Want to see PODD full AI Analyst Report?
PODD Stock Chart & Stats
$163.26
$4.88(3.08%)
At close: 4:00 PM EDT
$163.26
$4.88(3.08%)
Day’s Range― - ―
52-Week Range$126.40 - $354.88
Previous CloseN/A
Volume1.15M
Average Volume (3M)1.40M
Market Cap
$10.19B
Enterprise Value$10.98K
Total Cash (Recent Filing)$534.90M
Total Debt (Recent Filing)$948.40M
Price to Earnings (P/E)27.6
Beta0.30
Next Earnings
Oct 29, 2026EPS Estimate
1.59Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)5.36
Shares Outstanding69,354,200
10 Day Avg. Volume1,424,938
30 Day Avg. Volume1,404,203
Financial Highlights & Ratios
PEG Ratio-1.97
Price to Book (P/B)13.20
Price to Sales (P/S)7.38
P/FCF Ratio52.94
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$174.45Price Target Upside6.85% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering23
EPS Forecast (FY)6.5
Revenue Forecast (FY)$3.29B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables ModelOmnipod’s recurring pod-replacement cycle can support durable revenue visibility and customer retention. Each active patient generates ongoing consumables demand, making growth less dependent on one-time hardware purchases.
International And Access GrowthStrong international growth and broader payer access expand Insulet’s addressable market. Increased coverage and affordability can support new patient starts, improve adoption, and diversify growth beyond the U.S.
Margin And Earnings ExpansionManufacturing productivity and operating scale are translating into higher margins and strong earnings leverage. If sustained, this supports reinvestment in innovation while allowing profit growth to outpace revenue.
Bears Say
Type 2 Retention Execution RiskWeak onboarding and first-90-day retention among type 2 customers could reduce pod utilization, lifetime value, and recurring revenue growth. Corrective actions are underway, but their effectiveness remains unproven.
Product Quality And Recall RiskThe pod correction creates lasting risks to customer trust, regulatory scrutiny, operating costs, and retention. Even with replacements and sufficient supply, repeat quality issues could weaken Insulet’s competitive position.
Uneven Cash ConversionInsulet generates meaningful cash, but inconsistent conversion and recent free-cash-flow decline reduce financial flexibility. Ongoing manufacturing investment and meaningful debt could limit cash available for resilience or growth initiatives.
Insulet News
PODD FAQ
What was Insulet’s price range in the past 12 months?
Insulet lowest stock price was $126.40 and its highest was $354.88 in the past 12 months.
What is Insulet’s market cap?
Insulet’s market cap is $10.19B.
When is Insulet’s upcoming earnings report date?
Insulet’s upcoming earnings report date is Oct 29, 2026 which is in 68 days.
How were Insulet’s earnings last quarter?
Insulet released its earnings results on Aug 05, 2026. The company reported $1.66 earnings per share for the quarter, beating the consensus estimate of $1.468 by $0.192.
Is Insulet overvalued?
According to Wall Street analysts Insulet’s price is currently Undervalued.
Does Insulet pay dividends?
Insulet does not currently pay dividends.
What is Insulet’s EPS estimate?
Insulet’s EPS estimate is 1.59.
How many shares outstanding does Insulet have?
Insulet has 69,354,200 shares outstanding.
What happened to Insulet’s price movement after its last earnings report?
Insulet reported an EPS of $1.66 in its last earnings report, beating expectations of $1.468. Following the earnings report the stock price went down -20.117%.
Which hedge fund is a major shareholder of Insulet?
Currently, no hedge funds are holding shares in PODD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Insulet Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$174.45 (6.85% Upside)
$174.45 (6.85% Upside)
Blogger Sentiment
Bullish
PODD Sentiment 71%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Increased
By 241.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $838.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 4.1%
Last 30 Days ▼ 4.1%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-43.14%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-8.77%
Trailing 12-Months
Company Description
Insulet
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
PODD Company Deck
PODD Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a broadly positive operational and financial performance — strong revenue, significant margin expansion, robust EPS growth, international strength, product and clinical progress, and solid liquidity — while transparently acknowledging a meaningful, addressable execution issue in onboarding and retaining type 2 customers that led to a modest downward revision to U.S. revenue outlook and a reassessment of longer-term assumptions. Management presented concrete actions (expanded customer care, sales compensation changes, sampling refinements, Omnipod Discover and data platform investments) to remediate retention and utilization in the first 90 days and expressed confidence these will translate into improved outcomes over time.View all PODD earnings summariesPODD Revenue Breakdown
70.89% U.S. Omnipod
27.85% International Omnipod
1.26% Drug Delivery
PODD Stock 12 Month Forecast
Average Price Target
$174.45
▲(6.85% Upside)
Technical Analysis
Ownership Overview
0.33% Insiders
33.24% Mutual Funds
25.34% Other Institutional Investors
11.96% Public Companies and Individual Investors